Physician profile
David J Maddock
NPI 1376540443
$3,773.11
in general payments reported to CMS, 2019-2025
28 companies · $357 in 2025
The $357 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,359 · 2020: $636 · 2021: $17.12 · 2022: $109 · 2023: $958 · 2024: $337 · 2025: $357.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,652.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,652.12 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,118.94 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $531.67 | 2019-2024 | Entyvio |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $371.85 | 2019-2023 | Trulance, Xifaxan |
| Janssen Biotech, INC. | $255.69 | 2019-2020 | |
| Pfizer INC. | $215.49 | 2019-2023 | |
| Ironwood Pharmaceuticals, INC | $150.99 | 2019-2024 | |
| E.R. Squibb & Sons, L.L.C. | $117.69 | 2023 | |
| Neurocrine Biosciences, INC. | $116.15 | 2023 | Ingrezza |
| Intuitive Surgical, INC. | $98.47 | 2023 | Da Vinci Surgical System |
| Gilead Sciences, INC. | $92.00 | 2020-2023 | |
| Sumitomo Pharma America, INC. | $90.50 | 2023-2024 | Myfembree |
| Merck Sharp & Dohme LLC | $75.84 | 2019-2020 | |
| Ucb, INC. | $75.08 | 2019 | |
| Nestle Healthcare Nutrition INC. | $67.05 | 2020-2022 | |
| Genzyme Corporation | $63.77 | 2023 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celgene Corporation | $63.40 | 2023-2024 | Zeposia |
| Janssen Scientific Affairs, LLC | $39.08 | 2019 | |
| Intercept Pharmaceuticals, INC. | $34.24 | 2020-2022 | |
| Shire North American Group INC | $28.58 | 2019 | |
| Phathom Pharmaceuticals, INC. | $21.72 | 2024 | Voquezna |
| Concordia Pharmaceuticals INC. | $21.32 | 2019 | |
| Romark Laboratories, Lc | $19.59 | 2019 | |
| Organon LLC | $19.34 | 2023 | Renflexis |
| Ardelyx, INC. | $18.95 | 2023 | Ibsrela |
| Alfasigma USA, INC. | $18.39 | 2020 | |
| Allergan, INC. | $18.19 | 2019 | |
| Daiichi Sankyo INC. | $16.77 | 2020 | |
| Braintree Laboratories, INC. | $12.36 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Maddock listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.